FDA Classifies Enroute Carotid Recall as Class I

FDA has classified Boston Scientific's removal of specific lots of the ENROUTE Transcarotid Neuroprotection System as a Class I recall — the agency's most serious category, reserved for situations where there is a reasonable probability that use of the product will cause serious adverse health consequences or death. The removal covers roughly 165,000 devices across the ENROUTE Transcarotid Neuroprotection System and its Plus version, and traces to reports that the tip of the arterial sheath can separate during a procedure.

The defect

The reported failure is separation — complete or partial — of the arterial sheath tip during use. In a transcarotid revascularisation the sheath is placed directly into the common carotid artery, so a fragment that detaches does so upstream of the cerebral circulation. FDA and the manufacturer describe the downstream risks in the same terms: a retained tip may require endovascular or surgical retrieval, and the complications associated with one include embolism, stroke, transient ischaemic attack, restenosis, and thrombosis. Those are the harms the procedure itself is performed to prevent.

The reported harm to date is narrow. As of 9 July 2026, when Boston Scientific notified customers, the firm had reported one serious injury and no deaths associated with the issue. Class I classification does not require a body count; it turns on the reasonable probability of serious harm from the failure mode, which is why a single injury and a plausible mechanism can carry a recall into the top tier.

A test of the early alert programme

The sequence here is worth reading as a process story as much as a device one. Boston Scientific notified affected customers on 9 July, recommending they stop use, segregate product, and return it. FDA published an Early Alert on 24 July describing the arterial sheath tip separation and stating that it was reviewing a potentially high-risk device issue. The Class I classification came about a month later.

The Early Alert programme exists precisely to close that gap. Classification is a determination FDA makes after it has assessed the health hazard, and historically the public record moved at the speed of that determination — which meant clinicians could be weeks behind a firm's own field action. An early alert publishes the signal while the assessment is still running, without asserting a severity the agency has not yet fixed. For a device in active use in cerebrovascular procedures, the difference between learning in July and learning in August is not academic.

What this means operationally

• Inventory. Affected lots should be quarantined and returned per the firm's 9 July notification. Confirm lot coverage against the notification rather than assuming a whole catalogue number is implicated — the action is lot-specific.
• Complaint files. A Class I classification raises the expected scrutiny of how a facility handled the interval since the July notification; the paper trail from receipt to segregation is the part that gets examined.
• Reporting. Suspected device-related adverse events remain reportable through MedWatch regardless of whether they involve a lot named in the action.
• Procedural planning. Withdrawal of a substantial share of neuroprotection system inventory has a supply consequence for scheduled transcarotid revascularisation cases; alternative access strategies and device availability are worth confirming before the list is built rather than on the day.

What is still open

Two things are not yet settled in the public record. The first is root cause: neither the early alert nor the classification identifies why the tips separate, and a corrective action that returns product to the market depends on that answer. The second is scope over time. Recall records are amended as firms and the agency work through distribution data, and the unit counts reported at classification are the counts as understood at that moment. Facilities that have already segregated and returned product should keep watching the recall entry rather than treating the file as closed.